Skip to main content
TipRanks
Go Ultimate75% OFF

Croda International (49GP) AI Stock Analysis

5 Followers
GB:49GP

Croda International

(LSE:49GP)

Select Model
Rating:58Neutral
Price Target:GBX 90.00â–²(3.45% Upside)
Action:reiterated
Date:10/29/26

The overall score of 58 reflects a company with a strong financial foundation and positive near-term business momentum, offset by significant concerns. The primary positive driver is the upbeat earnings call, which confirms management's confidence in restoring growth and margins. This is supported by a healthy balance sheet and robust cash flow generation. However, the score is heavily constrained by a very high P/E ratio of 64.1, which prices in a strong recovery and leaves no room for error, and a recent history of sharply declining profitability. The stock's neutral technical trend provides no directional catalyst.

Positive Factors
Differentiated specialty ingredients modelCroda's differentiated ingredient technologies, technical expertise and customer co-development can support premium pricing and longer-term relationships. This business model is less dependent on undifferentiated volume and provides a foundation for durable margins across consumer, life sciences and industrial applications.
Negative Factors
Muted revenue growth and weaker net incomeLimited recent revenue growth reduces the operating leverage available to offset costs, while the sharp fall in net income shows that earnings have been materially less resilient than EBIT. Sustained bottom-line pressure could constrain reinvestment and weaken confidence in earnings quality.

Croda International (49GP) vs. iShares MSCI United Kingdom ETF (EWC)

0%5%10%15%20%25%GB:49GP+8.04%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 121.44M
Dividend Yield
7.59%
Average Volume (3M)
11.33K
Price to Earnings (P/E)
67.8
Beta (1Y)
0.04
Revenue Growth
―
EPS Growth
―
Country
UK
Employees
5,954
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

Croda International Business Overview & Revenue Model

Company Description

Croda International Plc, established in 1925 and headquartered in Goole, United Kingdom, is a global leader in the development, manufacture, and supply of high-performance specialty chemicals. The company serves a diverse international client base ac...

How the Company Makes Money

Croda makes money primarily by selling specialty chemical ingredients and ingredient systems to business customers (B2B) across its end-markets. Revenue is generated through (1) Consumer Care ingredient sales, where Croda supplies functional additive...

Croda International Earnings Call Summary

Earnings Call Date:Jul 28, 2026(Q2-2026)|% Change Since:0.00%|Next Earnings Date:Jul 25, 2018
Earnings Call SentimentPositive

The call conveyed a positive operational and financial momentum: sales and profits grew, margins expanded, transformation savings are materializing and innovation-led segments (notably Beauty Actives) delivered strong growth. There are clear executional achievements (new plants, digitalisation, NPP growth) and management reiterated unchanged full-year guidance. Notable challenges include phasing-related weakness in Pharma Solutions, disruptions in Fragrances & Flavours from Middle East conflict, crop end-market softness and elevated working capital/inventory. However, management signaled these are largely within control (pricing actions, order-book visibility, transformation roadmap) and expects H2 improvement.

Positive Updates

Revenue Growth in H1
Group sales increased 5% in constant currency to GBP 881 million, driven by volume (+1%) and price/mix (+4%). Organic guidance for the full year remains 3%–6%.

Negative Updates

Pharma Solutions Underperformance and Project Phasing
Pharma Solutions sales were below expectations in H1 due to project phasing; management described the business as lumpy/project-driven and expects order-book-led improvement in H2 but H1 weakness weighed on Life Sciences performance.

Company Guidance

Management reiterated unchanged 2026 guidance — organic sales growth of 3–6% and a further increase in adjusted operating margin, with adjusted operating profit expectations unchanged — saying the H1 exit rate and momentum give confidence to deliver full‑year margin expansion and to remain on track for the 3‑year / 2028 financial framework; H1 actuals supporting that view included group sales +5% to £881m, new & protected products +7%, volumes +1% and price/mix +4%, adjusted operating profit +7% to £156m and adjusted operating margin up to 17.7% (+50bp), EPS +9% to 78p, free cash flow £38m (from £28m), net debt £578m and leverage 1.4x EBITDA; transformation delivered £18m of savings in H1 (cumulative £46m toward a £100m target), CapEx was £43m, and working‑capital actions target ~£50m structural savings by 2028 to offset typical annual WC funding of £20–30m — with segment/region momentum (Consumer Care +8%, Pharma Ingredients +7%, Beauty Actives Q2 +27%, Asia +10%, Latin America +11%, North America -1%).

Croda International Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is solid with low leverage (debt-to-equity 0.35) and cash flow is strong, with free cash flow surging 115%. However, profitability has weakened significantly, with net income more than halving and margins compressing. The overall picture is of a financially stable company facing earnings headwinds.

Income Statement

35Negative

Balance Sheet

70Positive

Cash Flow

75Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.72B1.70B1.63B1.69B2.09B1.89B
Gross Profit615.90M608.70M733.90M730.00M864.90M825.60M
EBITDA390.10M380.70M374.50M388.50M924.80M549.40M
Net Income79.50M62.00M158.50M171.00M649.30M320.80M
Balance Sheet
Total Assets3.53B3.41B3.51B3.58B3.61B3.29B
Cash, Cash Equivalents and Short-Term Investments205.30M172.80M166.80M172.50M320.60M112.80M
Total Debt783.20M696.60M699.10M710.10M615.80M936.00M
Total Liabilities1.34B1.21B1.21B1.21B1.18B1.53B
Stockholders Equity2.17B2.19B2.28B2.35B2.42B1.75B
Cash Flow
Free Cash Flow187.80M171.80M137.60M156.80M160.90M190.50M
Operating Cash Flow283.40M289.50M319.40M337.50M313.30M349.20M
Investing Cash Flow-93.00M-109.80M-139.10M-409.80M418.10M-218.40M
Financing Cash Flow-175.90M-152.60M-182.60M-52.40M-550.90M-111.90M

Croda International Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

GB:49GP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
GB:SYNTGB:SYNT60NeutralGBP 168.21M-1.40-13.27%―-4.98%-43.98%
GB:VCTGB:VCT59NeutralGBP 750.01M-37.43-4.95%3.12%-1.24%-166.15%
GB:49GPGB:49GP58NeutralGBP 5.35B67.753.65%7.59%――
GB:JMATGB:JMAT56NeutralGBP 2.91B-33.30-6.76%4.53%26.60%14.94%
GB:ELMGB:ELM53NeutralGBP 1.05B18.8711.29%1.78%-11.73%―

* Basic Materials Sector Average

Performance Comparison

-50%0%50%100%GB:49GPGB:ELMGB:JMATGB:SYNTGB:VCTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:49GP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:49GPCroda International (49GP)87.006.478.04%
GB:ELMElementis plc186.8034.2522.45%
GB:JMATJohnson Matthey (Uk)2364.00417.6321.46%
GB:SYNTSynthomer plc102.6052.95106.65%
GB:VCTVictrex plc861.00310.2856.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026